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Parkinson’s disease (PD) is a common disorder of middle-aged and elderly people in which degeneration of the extrapyramidal
motor system causes significant movement problems. In some patients, however, there are additional disturbances in sensory
systems including loss of the sense of smell and auditory and/or visual problems. This paper is a general overview of the visual
problems likely to be encountered in PD. Changes in vision in PD may result from alterations in visual acuity, contrast sensitivity,
colour discrimination, pupil reactivity, eye movements, motion perception, visual field sensitivity, and visual processing speeds.
Slower visual processing speeds can also lead to a decline in visual perception especially for rapidly changing visual stimuli. In
addition, there may be disturbances of visuospatial orientation, facial recognition problems, and chronic visual hallucinations.
Some of the treatments used in PD may also have adverse ocular reactions. The pattern electroretinogram (PERG) is useful in
evaluating retinal dopamine mechanisms and in monitoring dopamine therapies in PD. If visual problems are present, they can
have an important eﬀect on the quality of life of the patient, which can be improved by accurate diagnosis and where possible,
correction of such defects.
1. Introduction
Parkinson’s disease (PD) is a common neurodegenerative
disorder aﬀecting middle aged and elderly people. It is a dis-
ease characterised by deficiency of dopamine in areas of the
midbrain causing a variety of movement problems such as
akinesia, rigidity, and tremor. Despite the emphasis on mo-
tor function in PD, nonmotor symptoms may also play a sig-
nificant role in determining the general quality of life of the
patient. Hence, the symptoms of PD can include depression,
apathy, sleep problems, cognitive impairment, dementia, and
autonomic, gastrointestinal, and sensory problems [1]. Sen-
sory problems may include visual loss, loss of smell, auditory
problems, and “restless legs” syndrome (RLS). Visual signs
and symptoms of PD may include defects in eye movement,
pupillary function, and in more complex visual tasks involv-
ing the ability to judge distance or the shape of an object
[2, 3]. The symptoms of PD can be treated successfully using
drug therapy or surgery, and these treatments may also
have visual side eﬀects. Hence, this paper provides a general
overview of (1) the visual signs and symptoms of PD, (2) the
areas of the eye and brain which may be aﬀected by
the pathology of PD, and (3) the adverse ocular reactions to
treatment.
2. Visual Symptoms in Parkinson’s Disease
PD is associated with a variety of visual problems and these
are summarised in Table 1.
2.1. Visual Acuity. PD patients often complain of poor vision
especially as the disease progresses resulting, in part, from
poor visual acuity [4], low contrast acuity being especially
aﬀected [5, 6]. Impaired visual acuity also appears to be a
risk factor for the development of chronic hallucinations in
PD [7]. Poor visual acuitymay be caused by lack of dopamine
in the retina, abnormal eye movements, or poor blinking and
is only marginally improved by drug therapy [6].
2.2. Colour Vision. Vision has been reported to be blurred
in PD to coloured stimuli [8] with reduced colour fusion
times [9] which indicate the accuracy of perception of mon-
ochromatic contours. A progressive deterioration of colour
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Table 1: Visual signs and symptoms of Parkinson’s disease (PD).
Ocular aspect Change in PD References
Visual acuity Poor, especially at low contrast
[6]
[4]
Colour vision
Vision blurred for coloured stimuli [8]
Shortened colour fusion time [9]
Progressive deterioration [10]
Visual fields
Increase in glaucomatous visual field defects [13]
Side eﬀects of surgery [14]
Saccadic eye movement
Reaction time and max. velocity of horizontal gaze slower [15]
Hypometria [16]
Amplitude increased after cued saccades [17]
Smooth pursuit movement
Aﬀected early in disease process [20]
Superimposed saccades [15]
Reduction in response magnitude [15]
Optokinetic Nystagmus Abnormal in some patients [15]
Convergence Impaired, associated with large exophoria, diplopia
[21]
[22]
Blink frequency Reduced, causing abnormal tear film, dry eye and reduced vision [23]
Blink reflex Habituation not observed [24]
Pupil diameter Larger after light adaptation with anisocoria [26]
Light reflex Longer latency
Constriction time Increased [26]
Contraction amplitude Reduced [23]
Contrast sensitivity (CS) Abnormal in some cases, intermediate to high frequencies [28]
Temporal processing
Impaired ability to track rapid fluctuations [32]
Duration perception aﬀected [33]
Flash ERG Reduced amplitude of “b” wave [35]
PERG
Reduced amplitudes. [35]
Specific defect at medium SF
Delayed P50 [36]
Cortical VEP Delayed P100
[45]
[46]
Chromatic VEP
Increased latency and reduced [44]
Amplitude (esp. blue-yellow)
ERP Abnormal. Delayed reaction times
[42]
[41]
Visuo-spatial
Diﬃculty in judging verticals, [48]
position of body parts, and in route-walking tasks [49]
Orientation and motion discrimination Impaired [50]
Facial perception Impaired ability to perceive and imagine emotional faces [51]
Visual hallucinations Chronic in 30–60% of treated cases [54]
Abbreviations: ERG: Electroretinogram, ERP: event-related potentials, PERG: Pattern electroretinogram, SF: Spatial frequency, VEP: Visual evoked potentials.
discrimination is also evident and is often associated with
impairments of higher motor function [10]. Using the Farn-
sworth-Munsell 100-hue test, however, colour visual dis-
crimination does not appear to be consistently impaired in
the early stages of PD [11].
2.3. Visual Fields. There have been few studies of visual field
defects in patients with PD [12]. Retrospective analysis of
ophthalmic charts from PD patients, however, using a cup-
to-disc ratio of 0.8 or greater to define glaucoma, revealed
glaucomatous visual field defects in approximately 24% of
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patients suggesting there may be an increased rate of glau-
coma in PD [13]. In addition, intraocular pressure (IOP)
was slightly higher in PD patients with glaucoma compared
with glaucoma patients without PD (mean 18.9 compared
with 16.0). Of eight PD patients with glaucoma, five were
considered to have low tension glaucoma. In one study, visual
fields were investigated in patients undergoing posterior
pallidotomy, a procedure which risks damaging structures
such as the optic tract [14]. Of 40 such patients, three had
visual field defects likely to be attributable to the surgery,
namely, contralateral superior quadrantanopia, associated in
two patients with small paracentral scotomas.
2.4. Saccadic and Smooth Pursuit Eye Movements. Assess-
ment of oculomotor function in PD can bemade clinically or
by using electro-oculography (EOG). EOG responses are
often normal in PD patients when the eyes are in the primary
position or when resting. Abnormal saccadic and smooth
pursuit eye movements, however, have been reported in
about 75% of patients [15]. Both reaction times and the
maximum saccadic velocity of horizontal gaze are slower in
PD [15]. Saccadic eye movements may exhibit hypometria,
that is, “under reaching of task” [16] while smooth pursuit
movements may be interrupted by small saccades [15].
In addition, the amplitude of saccadic eye movements are
increased in normal subjects when there is a change from
externally cued saccades to self-paced saccades and this eﬀect
is often greater in PD [17]. In a study in which the delay of
remembered (imagined) saccades was gradually increased in
untreated PD patients, there was a marked hypometria of
saccadic gain at all delays suggesting a dysfunction of the
striatocollicular inhibitory pathways in PD attributable to
dopamine deficiency in the basal ganglia [18]. In a further
experiment, spatial working memory was studied in relation
to eye movements [19]. A sequence of four targets was
memorised by the patient and then the eyes were moved
to fixate the targets in their correct order. In PD, several
discrete saccadic eye movements of reduced amplitude were
necessary before reaching the final eye position, and the
patients also exhibited an increasing proportion of errors
in remembering the target sequence. The results suggested
that memory representation was disrupted early in the
development of PD.
EOG recordings have been made before and after apo-
morphine treatment in patients with early-stage disease and
have confirmed that smooth pursuit movements are aﬀected
during the initial stages of the disease [20]. In addition,
patients with PD often have diﬃculty in sustaining repetitive
actions and hence, smooth pursuit movements exhibit a
reduction in response magnitude and a progressive decline
of response with stimulus repetition.
2.5. Nystagmus and Convergence. Abnormal optokinetic nys-
tagmus “train nystagmus” [15] and convergence [21] have
been reported in PD patients. Further abnormalities that
have been observed include “jerkiness”, “cogwheeling”, and
limitation of eye movement. Vertical eye movements are
often more impaired than horizontal movements. Conver-
gence can be associated with relatively large exophoria (out-
ward deviation of the eye), and the result is often diplopia
(double vision) [22].
2.6. Blink Reflex. Patients with PD exhibit a reduced fre-
quency of blinking leading to a staring appearance [23].
Reduced blink rate can cause an abnormal tear film, dry
eye, and reduced vision. A characteristic ocular sign may be
the blink reflex, elicited by a light tap above the bridge of
the nose, successive taps in normal individuals producing
less and less response as the reflex habituates [24]. In PD,
the blink reflex may not disappear on repeated tapping. In
addition, blink duration may be increased in PD reflecting
the loss of dopamine neurons [25].
2.7. Pupil Reactivity. Significantly larger pupil diameters,
with anisocoria (unequal pupil sizes) after light adaptation,
have been reported in PD [26], no diﬀerences being observed
after dark adaptation. In addition, longer light reflex latencies
and constriction times have been observed while contraction
amplitudes may be reduced [23]. These results suggest that
there is an autonomic imbalance in PD patients involving the
parasympathetic system.
2.8. Psychophysics. Contrast sensitivity (CS) is aﬀected in a
proportion of PD patients especially at the high or interme-
diate frequencies [27–29]. In some individuals, a substantial
decrease in CS can be demonstrated as the disease progresses
and could be a contributory cause of poor vision in PD.
Abnormalities in CS are likely to be related to dopamine dys-
function and are often orientation specific suggesting cortical
involvement [30]. L-dopa therapy generally improves CS
performance close to that of healthy control patients without
any neurological dysfunction. In addition, apomorphine
significantly improves achromatic spatial CS at all spatial
frequencies but appears to have minimal eﬀects on colour
vision [31].
There may be decreased sensitivity to temporally chang-
ing stimuli in PD which have been well demonstrated by
studies of the auditory system. Hence, in psychophysical tests
assessing auditory processing, bilateral subthalamic nucleus
stimulation caused dysfunction in ability to track rapid
fluctuations in sound intensity [32]. In addition, in motor
tasks involving finger tapping, a PD group were impaired
both in the motor task itself and in assessing duration
implicating the basal ganglia and thalamocortical connec-
tions in timing [33]. Subsequently, the substantia nigra, an
important site of PD pathology, was shown to be involved
in temporal processing involving motor and perceptual tasks
[34]. Problems in the visual perception of rapidly moving
stimuli are likely to cause problems in tracking fast moving
targets.
2.9. Electrophysiology. Significant changes in the electroret-
inogram (ERG) have been found in PD. Studies show that
the amplitude of the ERG “b” wave may be reduced in
PD patients under a variety of light conditions [35]. Since
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the amplitude of the “b” wave may be a diagnostic indicator
of the functioning of the inner nuclear layer, the reduction
may reflect defects in visual processing involving dopamine
neurons. In addition, the amplitude of the pattern ERG
(PERG) to a checkerboard stimulus is decreased [35] and the
latency of the P50 component delayed [36] in PD patients.
Subsequent studies have suggested that retinal dopamine
depletion may result in attenuated ERG responses to peak
stimuli [37]. Two dopamine sensitive pathways have been
postulated: (1) involving the D1 receptors which primarily
aﬀect the “surround” organisation of ganglion cells with
large centres and (2) the D2 postsynaptic receptors which
contribute to the “centre” response amplification of ganglion
cells with smaller centres. In addition, steady-state pattern
PERG to sinusoidal gratings was studied over a range of
spatial frequencies [38]. Aging aﬀected responses at all
spatial frequencies but the pattern of age-related loss was
diﬀerent in PD. In PD, there was a specific deficit at
medium spatial frequencies accompanied by a distorted
PERG spatial frequency response function. PERG is also
sensitive to dopamine manipulation in the monkey retina
[39]. In a further experiment involving the use of the
selective D2 blocker l-sulpiride, treatment aﬀected the PERG
to a sinusoidal vertical grating presented at four spatial
frequencies [39]. The data suggested that dopamine is
involved in retinal processing in primates and that the D2
receptor is necessary for spatial-temporal tuning of pattern
vision. Subsequently it was shown that the two dopamine
receptors play diﬀerent roles in retinal function and therefore
in the diﬀerent visual alterations in PD [40]. Hence, PERG
is useful in evaluating retinal dopamine mechanisms and in
monitoring dopamine therapies in PD.
Event-related potentials (ERP) employing various “odd-
ball” tasks have been used to study the sensory and cognitive
processing in PD. Abnormal ERP responses in PD often
correlate with worsening Wechsler and motor dysfunctional
scale scores [41]. In a study of the P300 response, believed
to reflect orientation, attention, stimulus evaluation, and
memory, reductions in reaction time were actually less in PD
than in other “parkinsonian syndromes” such as progressive
supranuclear palsy (PSP) and corticobasal degeneration
(CBD) [42].
Evoked responses to coloured stimuli are also aﬀected in
PD [43] supporting the hypothesis that dopamine modulates
the retinal colour system. In idiopathic PD, for example,
amplitude is decreased and latency increased for all chro-
matic stimuli and especially for those using blue-yellow (B-
Y) horizontal gratings [44], and this test may be a simple
tool for distinguishing diﬀerent parkinsonian syndromes.
Increased latency of the visually evoked potential (VEP) P100
peak to a checkerboard stimulus has been reported in a
proportion of patients suggesting a delay in visual processing
at one or more stages of the visual system [45–47].
2.10. Complex Visual Functions. There are prominent deficits
in PD involving neuropsychological tests requiring self-
motivation and a demanding response from the patient [1].
PD patients may exhibit a variety of deficits in visuo-spatial
orientation [48, 49] including diﬃculty in judging verticals
and the position of body parts, and in carrying out a route-
walking task. Visuo-spatial working memory appears to be
selectively impaired early in PD which probably reflects
degeneration of the basal ganglia, the dorsal visual stream,
and the frontal-prefrontal cortex [1]. Patients may also have
problems with memory tasks involving spatial orientation.
PD patients often show an impairment of orientation
and motion discrimination [50] suggesting that the visual
pathway beyond the retina may be aﬀected since these tasks
are most likely to involve the visual cortex. In addition,
impairments in the ability to perceive and imagine faces
have been reported in PD [51]. Medicated and unmedicated
patients exhibit facial recognition problems but these deficits
are most frequently present in the untreated group [52].
Normal subjects contract their facial muscles while imaging
faces, a process which is often impaired in PD patients. In
a problem solving task involving arranging coloured balls
in pockets on a computer screen, PD patients made more
errors on the task than controls and also did not show any
dissociation in the amount of time fixating the two halves of
the display [53]. The results suggested diﬃculties in encoding
and/or maintaining current goals during problem solving in
PD.
2.11. Visual Hallucinations. Visual hallucinations are a
chronic complication of PD [54, 55] and especially in pa-
tients treated with L-dopa and dopamine agonists. In a large
study of PD patients, hallucinations occurred in the previous
three months in 40% of patients examined. Hallucinations
were visual in 22% and auditory in approximately 10% of
patients [55]. Patients with minor hallucinations had higher
depression scores than those without. Three factors were the
best predictors of hallucinations, namely, severe cognitive
defects, daytime somnolence, and longer duration of disease.
Hallucinations in PD are often complex with flickering
lights, and illusionary misconceptions often preceding the
most common manifestation, namely, stereotypical colour-
ful images. Visual hallucinations may involve a disturbance
in the regulation of the gating and filtering of external per-
ception and internally generated visual images. Risk factors
for hallucinations in PD patients include poor primary vision
and reduced activity of the primary visual cortex (area V1).
3. Pathological Changes Affecting
the Visual System
3.1. Eye Pathology. Few pathological changes have been
reported in the eye in PD with the exception of the retina
[56]. However, the maximum contraction ability of the iris
muscle measured in vitro is greater in PD than in controls
suggesting that the muscle may have acquired adaptive
sensitivity changes [57].
Dopamine is an important neurotransmitter in the retina
and is present in amacrine cells and along the inner border
of the inner nuclear layer [58] (Figure 1). In addition,
dopamine may be accumulated by interplexiform cells [59].
Two types of amacrine cells appear to be involved. Type
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Figure 1: The layers of the retina (PE: pigment epithelium, PR:
visual receptors, ONL: outer nuclear layer, OPL: outer plexiform
layer, INL: internal nuclear layer, IPL: internal plexiform layer, GC:
ganglion cell layer, and SO: Stratum opticum). Dopamine neurons
(TOH+: Tyrosine hydroxylase positive neurons, Type 1 cells and
Type 2 amacrine cells) are primarily concentrated in the INL and
dopamine positive neurites (Type 1 in stratum 1 and type 2 ramify
above stratum 1) in the IPL. Type 1 cells may synapse onto GABA
interpelexiform cells (IPCs). Some dopamine activities may also be
observed in the ganglion cell layer.
1 cells send ascending processes to the outer plexiform
layer where they synapse with γ-aminobutyric acid (GABA)
interplexiform cells in stratum 1, whereas type 2 cells have
their dendrites stratifying above those of the type 1 cells
of the inner plexiform layer (Figure 1). Dopamine may be
involved in the organisation of the ganglion cell and bipolar
cell receptive fields and appears to modulate the physical
activity of the photoreceptors [60]. In addition, dopamine
is involved in the coupling of the horizontal and amacrine
lateral system [61].
Pathological changes which have been observed in the PD
retina include cell losses, which often aﬀect the peripheral
segments of the retina more severely and reductions in retinal
dopamine [62]. In addition, the thickness of the circum-
papillary retinal nerve fibre layer was studied using optical
coherence tomography (OCT) [63]. The inferior quadrant
layer, and especially the inferior temporal region, was signifi-
cantly thinner in PD than in controls. In normal subjects, the
foveola contains no dopamine neurons, innervation being
achieved by processes originating in the avascular zone. In
PD, swelling and loss of these processes has been observed.
These observations are consistent with the ERG data and
support the hypothesis that at least some of the cortical VEP
changes could be retinal in origin.
3.2. Brain Pathology. The surviving neurons of the substantia
nigra and cerebral cortex often contain inclusions called
Figure 2: Cells from the cerebral cortex showing the presence
of Lewy bodies (α-synuclein immunohistochemistry, haematoxylin
stain, bar = 25 μm).
A9
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Figure 3: The dopamine projections of the central nervous system
(OB: Olfactory bulb, SFC: superior frontal cortex, CG: Cingulate
gyrus, ST: Striatum, HY: Hypothalamus, VT: Ventral tegmentum,
SN: Substantia nigra).
Lewy bodies (LB) (Figure 2). LB are found in the cytoplasm
of the cell and may be derived from cytoskeletal filaments.
Recent research suggests that LB diﬀer significantly from
other neurofibrillary pathologies in neurodegenerative dis-
ease, for example, the neurofibrillary tangles (NFT) found
in AD [64], in that they contain abnormal aggregates of the
protein α-synuclein [65]. α-Synuclein is a small presynaptic
protein and the entire molecule undergoes a conformational
change to result in the insoluble protein that forms a major
component of the LB.
There are two major dopamine pathways in the brain
(Figure 3). First, there is the striatonigral pathway from the
substantia nigra (cell group A9) to the cortex and stria-
tum. Second, a major pathway originates in the ven-
tral tegmentum (cell groups A8, A10) and projects to the
amygdala, septum, nucleus accumbens, olfactory tubercle,
and frontal cortex. There are also dopamine pathways
within the hypothalamus. Hence, within the brain significant
dopamine activity is limited to the frontal and limbic areas of
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Table 2: Adverse ocular reactions to treatment for Parkinson’s disease.
Treatment Examples Ocular side eﬀects
Anticholinergi Benzhexol, Diphenydramine Mydriasis, photophobia, dry eyes, decreased accommodation, anisocoria, blurred
vision, anterior angle closure
Dopamine agonists
Bromocriptine May exacerbate visual hallucinations
Pramipexole May exacerbate visual hallucinations
Ropinirole May exacerbate visual hallucinations
L-dopa L-dopa/carbidopa Mydriasis, miosis, blepharospasm eyelid ptosis, may prolong latency of saccades
MAO inhibitors Selegiline May cause loss of visual acuity and blurred vision
Antiviral Amantadine Mydriasis, superficial keratitis, reduced accommodation, hallucinations
Antidepressant Imipramine Mydriasis, cycloplegia, dry eyes, ocular muscle paresis, nystagmus
the cerebral cortex with significantly less activity in the visual
cortex [62]. Cerebral metabolic rates for glucose, however,
are reduced by up to 23% in the primary visual cortex of
PD patients [66]. Reductions in dopamine levels in the
basal ganglia and frontal cortex may also deplete levels in
the superior colliculus and thus could be a factor in the
production of defective saccades [16].
Within the cerebral cortex, functional MRI (fMRI) and
EEG studies have both revealed the essential role of the occip-
ital cortex in producing saccadic eye movements while PET
studies have revealed occipital hypometabolism in these
areas in PD. In addition, in a study using “event-related”
fMRI and which utilised a visual attention/motor inhibition
task, during motor inhibition there was activation of the
prefrontal cortex and basal ganglia [67]. In addition, there
was a reduced and less coherent haemodynamic response
in the occipital cortex. Hence, specific functional changes
involving the frontostriatal network and temporal-occipital
cortex were present in the early stages of PD. PD patients with
damage to the medial temporal lobe perform the poorest in
all explicit memory tasks and memory problems are often
apparent in this group in early stage disease [68].
In subcortical regions, areas of the basal ganglia appear
to be the most aﬀected by the developing pathology. Within
the basal ganglia, the substantia nigra pars reticulata, the
subthalamic nucleus, and the caudate nucleus are all involved
in saccadic eye movements [69]. There is, however, an
overlap in the anatomical pathways involved in saccadic and
smooth pursuit movements which may explain why both
are aﬀected in PD. Dopamine also has a peripheral role in
sympathetic ganglia, visceral ganglia, and in all artery walls.
Hence, reductions in dopamine in some of these areas could
be a factor contributing to eye movement problems and
defects in pupil reactivity.
4. Adverse Ocular Reactions to Treatment
There are several drugs given alone or in combination used to
treat PD (Table 2). Most act on the brain either by reducing
cholinergic activity or by encouraging dopamine activity in
the basal ganglia [70].
Anticholinergic drugs such as benzhexol and dipheny-
dramine act to decrease acetylcholine levels, the eﬀect of
which is enhanced by the lack of dopamine. Benzhexol may
have a significant mydriatic eﬀect and therefore, should not
be given to patients with anterior angle closure and should be
used with caution in those with a narrow anterior chamber
angle. Prolonged exposure to this drug in a few patients
may cause an angle closure of gradual onset but without
acute symptoms. Optometrists may be the only health
practitioners aware of this risk, that is, it is always important
to assess anterior chamber depth in PD patients. In addi-
tion, photophobia and decreased accommodation can occur
resulting in blurred vision [71].
Dopamine agonists such as bromocriptine, pramipexole,
and ropinirole enhance the eﬀect of dopamine by directly
stimulating dopamine receptors. Pramipexole and ropinirole
are often indicated as a treatment for early stage PD and
RLS. These drugs may cause less motor complications and
dyskinesia than L-dopa but are often given in combination
with the latter. Use of dopamine agonists may exacerbate
visual hallucinations in PD.
L-dopa is a precursor of dopamine and can penetrate the
blood-brain barrier more successfully than dopamine itself.
It is often given with a peripheral decarboxylase inhibitor,
for example, carbidopa, to reduce the breakdown of L-dopa
outside the brain. Mydriasis may occur at first, and this may
be followed by miosis. Lid ptosis and blepharospasm have
been reported in a few patients [72]. In addition, L-dopamay
prolong the latency of saccades [73].
Monoamine oxidase B (MAO-B) inhibitors, such as selig-
inine, slow down the breakdown of dopamine at the synapse.
Patients treated with MAO-B inhibitors and multiple ergot-
amine-derived dopamine agonists may exhibit blurring of
vision [74].
The antiviral drug amantadine appears to have a bene-
ficial eﬀect on many of the symptoms of the disease. A few
adverse reactions have been reported including a superficial
keratitis, mydriasis and reduced accommodation while in
some patients visual hallucinations may occur [75]. By
contrast, imipramine has antidepressant and anticholinergic
properties and acts by inhibiting the reuptake of dopamine.
Ocular side eﬀects include mydriasis, cycloplegia, dry eyes,
nystagmus, and the paresis of ocular muscles.
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5. Discussion and Conclusions
Patients who have been diagnosed as having PDmay develop
a range of visual problems during the course of the disease.
Hence, changes in vision in PD may result from alterations
in visual acuity, contrast sensitivity, colour discrimination,
pupil reactivity, eye movements, motion perception, visual
field sensitivity, and visual processing speeds. Slower visual
processing speeds can also lead to a decline in visual
perception especially for rapidly changing visual stimuli.
In addition, there may be disturbances of visuo-spatial
orientation, facial recognition problems, and chronic visual
hallucinations. Some of the treatments used in PD may
also have adverse ocular reactions. Visual deficits in PD
are important in influencing overall motor function [10],
are a risk factor for developing hallucinations [7] and are
important in influencing general quality of life [7]. Hence,
identifying and correcting the visual problems as far as
possible can significantly benefit a PD patient.
Clinical examination of the patient by eye practitioners
requires sensitivity to both the physical disability and mental
state of the patient and the problems involved have been
described in detail by Naylor [70]. Some of the visual
problems may be adverse reactions to treatment. Side eﬀects
may occur relatively rapidly at the beginning of, or after a
change, in drug treatment, but can also occur after a long
latent period. It is important that those symptoms due to
adverse reactions are distinguished from those due to the
disease process itself. If ocular side eﬀects are identified and
become severe, then it is essential that these are monitored
and the patient referred back to their physician for further
clinical assessment.
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